Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GridAI Technologies Corp.FWBI · Entity 7534 | CHIEF MEDICAL OFFICER | January 03, 2022 | January 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GridAI Technologies Corp.
Report date January 03, 2022 · Filed January 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2032-01-03 | Direct | 7,500 |
Reported balance
After 2022-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 7,500 · Balance 7,500 F1: The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Pennington's continued employment by First Wave BioPharma, Inc. on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Pennington's continued employment by First Wave BioPharma, Inc. on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 3, 2022 21:07 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantStock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-22-000300 · form4.xml · derivative · entry 1 Pennington James · CIK 0001668704 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common stock, par value $0.0001 per share · 7,500 shares Expires 2032-01-03 F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Pennington's continued employment by First Wave BioPharma, Inc. on the applicable vesting date. Read SEC document |
| July 09, 2021 Filed Jul 9, 2021 17:11 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-21-003573 · form4-07092021_020744.xml · derivative · entry 1 Pennington James · CIK 0001668704 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock, par value $0.0001 per share · 100,000 shares Expires 2031-07-09 F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Pennington's continued employment by AzurRx BioPharma, Inc. on the applicable vesting date. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:54 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-20-001939 · form4-07202020_060736.xml · derivative · entry 1 Pennington James · CIK 0001668704 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common stock, par value $0.0001 per share · 300,000 shares Expires 2030-07-15 F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on August 16, 2020, conditioned on Mr. Pennington's continued employment by AzurRx BioPharma, Inc. on the applicable vesting date. Read SEC document |
| June 13, 2019 Filed Jul 20, 2020 21:53 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantStock option (right to buy) · Derivative | 110,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001415889-20-001938 · form4-07202020_060734.xml · derivative · entry 1 Pennington James · CIK 0001668704 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common stock, par value $0.0001 per share · 110,000 shares Expires 2024-06-12 F1 · derivative.exercise_date: The stock option vests, if at all, upon the achievement of certain specified performance targets. Vesting is conditioned on Mr. Pennington's continued employment by AzurRx BioPharma, Inc. on the applicable vesting date. Read SEC document |
| July 12, 2018 Filed Jul 19, 2018 13:20 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 75,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001415889-18-001136 · form4-07192018_100730.xml · derivative · entry 1 Pennington James · CIK 0001668704 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2023-06-28 F1 · derivative.exercise_date: Options with respect to 37,500 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 37,500 shares vest upon the the first CF patient dosed with MS1819 anywhere in the globe. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.